NDSN · Q3 2025 Earnings

Cautious

Nordson Corporation

Reported August 20, 2025

30-second summary

30-second take: Nordson printed $741.5M in Q3 revenue (+12.1% YoY, top of the $710–750M guide) and $2.73 non-GAAP EPS (near the high end of $2.55–2.75), with Advanced Technology Solutions +17% and Medical and Fluid Solutions +32% (Atrion-led) more than offsetting Industrial Precision Solutions at flat +0.5%. Despite the beat, management now expects full-year revenue "slightly below the midpoint" of original guidance while EPS lands "slightly above the midpoint" — a quiet sales cut paired with margin-driven EPS comfort. Backlog fell ~5% sequentially and management is preemptively flagging tougher ATS comps in Q4; the print is a beat, but the forward signals are softer than the headline suggests.

Headline numbers

EPS

Q3 FY2025

$2.73

Revenue

Q3 FY2025

$0.74B

+12.1% YoY

Gross margin

Q3 FY2025

54.8%

Free cash flow

Q3 FY2025

$0.23B

Operating margin

Q3 FY2025

25.3%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$0.74B	+12.1%	$0.68B	+8.6%
EPS	$2.73	—	$2.42	+12.8%
Gross margin	54.8%	—	54.7%	+10bps
Operating margin	25.3%	—	24.7%	+60bps
Free cash flow	$0.23B	—	—	—

Guidance

Q3 FY2025 beat both revenue and EPS guidance; full-year revenue guidance slightly below midpoint while earnings expected slightly above midpoint.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q3 FY2025	$710 million to $750 million	$741.5 million	in-line (midpoint $730M; actual $741.5M at high end of range)	Beat
Adjusted EPS	Q3 FY2025	$2.55 to $2.75	$2.73	+$0.08 above midpoint ($2.65); within range at high end	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	FY2025	slightly below midpoint of full year sales guidance	—
Adjusted EPS	FY2025	slightly above midpoint of full year guidance	—

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Industrial Precision Solutions	$0.351B	+0.5%
Medical and Fluid Solutions	$0.219B	+31.6%
Advanced Technology Solutions	$0.171B	+17.4%
Industrial Precision Solutions EBITDA Margin	37%	—
Medical and Fluid Solutions EBITDA Margin	38%	—
Advanced Technology Solutions EBITDA Margin	24%	—

Other KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Americas	$0.315B	+9.6%
Europe	$0.187B	+4.0%
Asia Pacific	$0.24B	+23.1%
EBITDA	$239 million	—
EBITDA Margin	32%	—
Organic Sales Growth	2.1%	—
Acquisition Impact	7.8%	—
Free Cash Flow Conversion	180%	—

Management tone

Narrative arc: Q2 ATS reacceleration + IPS restructuring → Q3 multi-segment trough call with forward caution.

Three quarters of evolving framing on IPS deserve attention. Last quarter management positioned IPS as structurally challenged but actively being restructured with >$15M of 2026 savings teed up. This quarter the language softened further: "we believe this business has hit its trough" and "we expect the IPS segment to improve sequentially and return to normal growth rates." The shift from "we're cutting costs while we wait" to "we believe we're at the bottom" is meaningful, but the hedging verbs ("believe", "expect") and the fact that IPS only grew 0.5% — not negative, not normal — leaves the trough call unconfirmed.

ATS framing pivoted from confident growth to managed expectations. Last quarter the line was "we are now seeing it in our businesses and we're seeing it in our results" with HPC/semi now ~50% of ATS. This quarter management preemptively introduced two caveats: "we will start to come up against tougher comparisons starting in the fourth quarter" and "demand in this business inherently is lumpy based on the needs and timing of our customers." After two strong quarters, management is deliberately taking the air out of the linear-extrapolation thesis — not because anything broke, but because they don't want to own a setup they can't control.

The full-year guidance posture flipped from non-committal to a soft sales cut. Last quarter management dodged reiterating a specific FY range. This quarter they took a position and that position is below the midpoint on sales, above on EPS. The phrasing "Benefiting from the strong third quarter, we now expect to be slightly below the midpoint" is doing a lot of work — Q3 beat the guide, yet the FY outlook moved down. The unstated implication is that Q4 will undershoot prior internal expectations. EPS holding above midpoint says operational execution and mix are protecting earnings, but the demand picture is softer than the original FY plan assumed.

Medical destocking framing shifted from "severity reducing" to "normalized, with normal growth expected in fiscal 2026." That is a cleaner statement than last quarter and is backed by the interventional business going from negative to +4% organic ex-divestiture. The fiscal 2026 timing, however, means MFS organic-ex-Atrion will not be a clean tailwind until at least two more quarters from now.

Recurring themes management leaned on this quarter:

ATS double-digit organic growth acceleration driven by semiconductor/AI backend packaging demandMedical segment normalization post-destocking with improved interventional solutions trajectoryPolymer processing and automotive exposure weakness showing signs of stabilizationStrong free cash flow conversion (180% of net income) and leverage improvement to 2.2xNBS Next operational framework driving margin expansion and integration synergiesAtrion acquisition accretive one year ahead of original timeline

Risks management surfaced:

Geopolitical and trade policy uncertainty creating dynamic and mixed market conditionsAutomotive exposure weakness persists despite broader end market dynamicsATS demand is inherently lumpy based on customer timing and needsTougher year-over-year comparisons beginning in fiscal Q4 for ATS segmentContinued pressure in polymer processing and cold material product lines for automotive systems

Q&A highlights

Jeffrey D. Hammond · KeyBank Capital Markets

Order momentum across businesses, particularly ATS with tougher comps and medical destocking; explanation for sequential backlog decline.

Management attributed backlog decline to strong Q3 shipments, not weakening demand. Confirmed good order intake stability across all three businesses. ATS showing multi-year growth cycle with 8% growth over nine months; medical returning to growth with high single-digit growth in fluid components and destocking normalized in interventional business.

ATS up 8% over nine months (Q1 down, Q2 and Q3 strongly up)Medical fluid component business: high single-digit growthInterventional component business: flat in quarter, would have been 4% organic growth excluding pending divestitureIPS precision ag demand very strong in Europe and South America

Michael Pezendorfer · Baird Equity Research

Clarification on ATS cycle improvement assumptions vs. potential pull-forward in semiconductor complex; color on dispense, TNI, acoustic, x-ray, and 3D optical product lines.

Management stated no direct evidence of customer pull-forward requests; seeing broad-based stable demand across electronics dispense, acoustic and optical products. Emphasized new product development as key competitive advantage alongside operational excellence and agility. Also discussed balanced capital allocation approach with $212M in YTD share repurchases and healthy M&A pipeline; Atrion acquisition achieving EPS accretion a year ahead of schedule.

No direct evidence of customer pull-forward activityNew products launching to address customer complex chip needsATS competitive advantages: technology, new products, operational excellence, agility$212 million in YTD share repurchases

Edward Maggi · BNP Paribus

Why guidance improved only to 'slightly below midpoint' vs. 'low end' if Q3 was strong and tariff uncertainty has eased; details on CDMO divestiture charges.

Management acknowledged modest improvement from low-end guidance to slightly below midpoint, driven by Q3 performance but tempered by dynamic economic environment and continued tariff uncertainty. CDMO divestiture charge of $12.2M represents write-down to fair value plus small restructuring costs; no material further charges expected in Q4 close.

Improved guidance from 'low end' to 'slightly below midpoint' of rangeCDMO divestiture charge: $12.2 million (fair value write-down plus restructuring)Expected Q4 CDMO business close on trackEconomic environment remains dynamic with tariff uncertainties

Walter S. Liptak · Seaport Research Partners

AI technology impact on consumer electronics redesign across product portfolio; IPS quote-to-order cycle recovery given tariff-related capital deployment pause.

On AI: Early stages with focus on three value drivers - customer value creation, software subscription services (early in X-Ray business), and customer AI usage of products. On IPS: 60-70% of business showing good order momentum; pauses seen in plastics and industrial coatings (systems), but customer pipelines robust and not declining. Plastics pipeline rebuilding and business hitting trough with recovery underway, though large system orders still delayed.

AI subscription services being developed in X-Ray business (early stages)IPS 60-70% in good order position (packaging, non-wovens, product assembly)Plastics business hit trough, pipeline rebuilding but large system orders delayedIPS 50-50 split between systems and recurring revenue provides stability

Brad Hewitt · Wolf Research

Explanation for implied flat to slightly down year-over-year organic growth in Q4 despite momentum; ATS margin run-rate assumptions and FY26 incremental margin expectations.

Q4 year-over-year deceleration driven by tough prior-year comps in systems businesses (plastics notably). Sequential analysis shows modest Q3-to-Q4 uptick in absolute sales. ATS margins normalized around 24-25% EBIT at current revenue levels; cautioned against assuming expansion due to high R&D investment (14-15% of revenue) and SG&A load relative to other business units.

Q4 shows modest sequential sales uptick from Q3 despite tougher year-over-year compsATS historical repositioning during downturn has enabled strong current incremental performanceATS normalized EBIT margin: 24-25% at current revenue run ratesATS R&D investment: 14-15% of revenue (materially higher than other segments)

Answers to last quarter's watch list

IPS organic inflection in Q3 — IPS came in at +0.5% YoY, technically positive but not the "return to normal" management had implied. They moved the goalpost: now expecting sequential improvement and a return to normal rates "as selected markets stabilize.".

Continue monitoring

MFS organic ex-Atrion moving from -10% toward zero — Interventional was flat reported but +4% organic excluding the pending CDMO divestiture; fluid components grew high single digits. The destocking-severity narrative is now validated, with management expecting "normal organic growth in fiscal 2026.".

Resolved positively

ATS book-to-bill and sustainability of +18% organic pace into Q4 — ATS grew +17.4% in Q3 (slight deceleration). Management preemptively flagged tougher Q4 comps and reiterated that demand is "inherently lumpy." Brad Hewitt's exchange implied Q4 organic growth will be roughly flat-to-down YoY. The momentum is real but Q4 will not extend it.

Resolved negatively

Whether management reiterates a specific FY range vs. continues to dodge — Management took a position: revenue "slightly below midpoint", EPS "slightly above midpoint" of original FY guide. That is the first specific FY directional commitment in two quarters, and it is a soft sales cut.

Resolved negatively

Medical divestiture close timing and ~100bps margin accretion claim — CDMO close is on track for Q4, charge taken at $12.2M. The 100bps margin accretion claim has not been re-validated this quarter — that will be a Q4 print item.

Continue monitoring

IPS restructuring completion and >$15M run-rate benefit showing up in Q4 segment margins — IPS EBITDA margin printed 37% in Q3, which is healthy, but the company did not break out the restructuring-driven savings explicitly. The proof will be in the Q4 segment margin walk.

Continue monitoring

What to watch into next quarter

Whether Q4 IPS organic growth actually accelerates from +0.5%, or whether the "trough" call needs another quarter to validate — automotive exposure within IPS and ATS both remain explicit headwinds

Q4 ATS organic growth against the tough prior-year comp — management implied flat-to-down YoY; anything worse than -3% would suggest the +17% pace was more lumpy than structural

Final FY2025 revenue and EPS prints relative to the "slightly below / slightly above midpoint" framing — the dollar gap between these two outcomes is what tells you how much margin is doing the heavy lifting

IPS Q4 segment EBITDA margin and whether the >$15M annual restructuring benefit shows through as guided

CDMO divestiture close confirmation and explicit ~100bps medical segment margin accretion in Q1 FY2026

Backlog trajectory — another sequential decline would shift the "strong shipments, not weak demand" explanation from credible to suspect

Any change in M&A pace given Atrion's year-ahead accretion and $212M YTD buybacks signaling capital deployment confidence

Sources

Nordson Corporation Q3 FY2025 press release — https://www.sec.gov/Archives/edgar/data/72331/000007233125000112/ndsn-q320258kxex991.htm
Nordson Corporation Q3 FY2025 earnings call transcript

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.